Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
Fella MazouzMélanie BertineRomain CoppéeAlexandre StortoChristine KatlamaRoland LandmanAndré CabiéGilles PeytavinFrançois RaffiYazdan YazdanpanahDiane DescampsVéronique JolyJade GhosnCharlotte Charpentiernull nullPublished in: The Journal of antimicrobial chemotherapy (2023)
Whereas no significant change in the proportion of patients with APOBEC3-defective proviruses was evidenced after 1 year of dolutegravir + lamivudine maintenance, enrichment in APOMuts was observed. Further longer-term studies are needed to assess the other forms of defective viruses with dual-therapy.
Keyphrases
- hiv infected patients
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- high glucose
- study protocol
- preterm infants
- diabetic rats
- circulating tumor
- hiv testing
- clinical trial
- hepatitis c virus
- cell free
- single molecule
- men who have sex with men
- phase ii
- drug induced
- stem cells
- case control
- gestational age
- nucleic acid
- replacement therapy